MedTrace Logo

Metabolic Health Improvement Program: Effects of a Workplace Sugary Beverages Sales Ban and Motivational Counseling

NCT05972109 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 604

Last updated 2026-02-23

No results posted yet for this study

Summary

The purpose of the study is to test the impact of a multilevel workplace intervention (hospital-wide sales ban on sugar-sweetened beverages (SSBs) and individual-level brief counseling) on employee health.

Conditions

  • Obesity, Abdominal
  • Insulin Sensitivity

Interventions

OTHER

Workplace SSB sales ban

Environmental Intervention. The hospital food services will replace sugary drinks with non-sugar added alternative beverages throughout the campus.

BEHAVIORAL

Brief Intervention

Participants receive single-session brief intervention, which is an intervention that uses motivational interviewing, and helps participants understand amount and effect of their baseline SSB intake, identify realistic goals for reduction and overcoming obstacles.

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Sutter Health

    collaborator OTHER

  • California Pacific Medical Center Research Institute

    collaborator OTHER

  • University of California, San Francisco

    lead OTHER

Principal Investigators

  • Laura A Schmidt, Ph.D · University of California, San Francisco

  • Elissa Epel, Ph.D · University of California, San Francisco

  • Jamey Schmidt · Sutter Health/California Pacific Medical Center Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2025-12-01
Completion
2026-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05972109 on ClinicalTrials.gov